-
03:13:45 AM

RDY Stock News

01/20/23 6:30 AM
NYSE : RDY
clinical trial
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
Reddy’ s Laboratories Ltd., a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets such as the United States, Europe and other regions. DRL_RI is being developed as a biosimilar of rituximab, a cluster of...
RHEA-AI
very positive
12/19/22 8:00 AM
NYSE : RDY
clinical trial
Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
Reddy’ s Laboratories Ltd., a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase 1 study. Pharmacokinetic equivalence of DRL_TC to the EU reference medicinal product* and the U.S. reference product** was successfully demonstrated. The clinical trial also...
RHEA-AI
neutral
10/11/22 7:57 AM
NYSE : RDY
World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network
Reddy’ s largest manufacturing facility in Bachupally, Hyderabad, joins Global Lighthouse Network of the World Economic Forum Journey started four years ago with digitisation of infrastructure and processes. Reddy’ s Laboratories Ltd., a global pharmaceutical company, today announced the recognition of its largest manufacturing facility in Bachupally,...
RHEA-AI
positive
09/07/22 1:28 PM
NYSE : RDY
Dr. Reddy';s Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
Dr. Reddy’ s Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID ® Capsules approved by U.S. Food and Drug Administration. Reddy’ s with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. in settlement of...
RHEA-AI
neutral
07/29/22 1:24 PM
NYSE : RDY
Dr. Reddy';s Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
Reddy’ s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC, to acquire rights in Slayback’ s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify ® in U.S. Lumify ® is an over-the-counter eyedrop that can be used to relieve redness of the eye...
RHEA-AI
neutral
07/27/22 3:26 AM
NYSE : RDY
Dr. Reddy';s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
Reddy’ s Laboratories Ltd. today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade ® Injection, in the U.S. market approved by the U.S. Food and Drug Administration. The Velcade ® Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA...
RHEA-AI
neutral
07/22/22 6:17 AM
NYSE : RDY
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
Dr. Reddy’ s Laboratories Ltd. today announced the first-to-market launch of over-the-counter Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D ® 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration. Allegra-D ® 24 HR had U.S....
RHEA-AI
neutral
07/08/22 11:48 AM
NYSE : RDY
Dr. Reddy';s Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
Reddy’ s Laboratories Ltd. announces the launch of Dr. The Toviaz ® brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022 according to IQVIA. Reddy’ s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
RHEA-AI
neutral
07/05/22 3:30 AM
NYSE : RDY
partnership
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization. Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization...
RHEA-AI
very positive